Creative Planning’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Creative Planning’s Portfolio OMED Stock Details OMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-350	Closed	-$1K	–	4676
2017 Q2	$1K	Buy	350 +150	+75%	+$622	﹤0.01%	4585
2017 Q1	$2K	Buy	+200	New	+$1.76K	﹤0.01%	4386
2016 Q4	–	Sell	-300	Closed	-$3K	–	5119
2016 Q3	$3K	Hold	300	–	–	﹤0.01%	4190
2016 Q2	$4K	Hold	300	–	–	﹤0.01%	3836
2016 Q1	$3K	Hold	300	–	–	﹤0.01%	3895
2015 Q4	$7K	Buy	300 +150	+100%	+$3.07K	﹤0.01%	3558
2015 Q3	$2K	Buy	+150	New	+$3.01K	﹤0.01%	4047

Other funds holding OMED

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

ASP

Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Creative Planning's OMED Position: Q3 2017 in Review

Creative Planning sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q3 2017, closing a stake of 350 shares — an estimated $1K sold.

Creative Planning first reported a position in OMED in Q3 2015 and held it in 7 quarters. The position peaked at $7K in Q4 2015. 58 funds tracked by Wall St. Rank hold OMED as of Q3 2017.

Creative Planning reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
Creative Planning sold 350 OncoMed Pharmaceuticals, Inc. shares in Q3 2017, an estimated $1K.
Creative Planning first reported a position in OncoMed Pharmaceuticals, Inc. in Q3 2015 and held it in 7 quarters.
Creative Planning's OncoMed Pharmaceuticals, Inc. position peaked at $7K in Q4 2015.
58 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q3 2017.

Based on Creative Planning's 13F filing for Q3 2017, filed 17 Oct 2017.